(Total Views: 576)
Posted On: 02/09/2021 9:55:34 AM
Post# of 155816
The leronlimab/vyrologix stars are good
-P2 CD10 Covid19 safer than standard of care
-hundreds of HIV patients prove it is safe over years
-P3 CD12 Covid19 reviews- continue on without changes
-open label extension
-Medicare billing code
-P3 CD12 Covid19 approximately 87 out of 390 didn't make it overall (both arms) which means the entire trial mortality (22%) is better than standard of care in zyesami (30%). When we hear of CD12 details, the Leronlimab treatment arm will IMO show less than a 20% mortality rate and will be a big improvement over the standard of care mortality rate.
To me it looks like Leronlimab will soon be a very nice tool to have.
IMHO
-P2 CD10 Covid19 safer than standard of care
-hundreds of HIV patients prove it is safe over years
-P3 CD12 Covid19 reviews- continue on without changes
-open label extension
-Medicare billing code
-P3 CD12 Covid19 approximately 87 out of 390 didn't make it overall (both arms) which means the entire trial mortality (22%) is better than standard of care in zyesami (30%). When we hear of CD12 details, the Leronlimab treatment arm will IMO show less than a 20% mortality rate and will be a big improvement over the standard of care mortality rate.
To me it looks like Leronlimab will soon be a very nice tool to have.
IMHO
(12)
(0)
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.
